TPBG
BVS icon

Turning Point Benefit Group’s Bioventus BVS Stock Holding History

Turning Point Benefit Group’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5
Closed -$37 – 196
2025
Q4 		$37 Hold
5
– – ﹤0.01% 835
2025
Q3 		$33 Buy
+5
New +$35 ﹤0.01% 749

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Turning Point Benefit Group's BVS Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Bioventus (BVS) in Q1 2026, closing a stake of 5 shares — an estimated $37 sold.

Turning Point Benefit Group first reported a position in BVS in Q3 2025 and held it in 2 quarters. The position peaked at $37 in Q4 2025. 157 funds tracked by Wall St. Rank hold BVS as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Bioventus position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 5 Bioventus shares in Q1 2026, an estimated $37.
  • Turning Point Benefit Group first reported a position in Bioventus in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Bioventus position peaked at $37 in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.